
Release date: 2024-08-08 16:44:37 Article From: Lucius Laos Recommended: 307
Exkivity effectively inhibits the growth and spread of tumor cells by precisely targeting EGFR exon 20 insertion mutations, providing a new treatment option and hope for patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.
As a targeted treatment for lung cancer, Exkivity has shown certain effects in tumor treatment, but also has certain side effects. The severity of these side effects varies from person to person, but most are reversible and can be controlled with proper administration and dose adjustments.
Interstitial lung disease (ILD)/lung inflammation is one of the serious adverse effects that can be triggered by Exkivity, a complication with potentially serious consequences, which may not only lead to extensive damage to lung structures but also may further threaten the patient's life. For patients receiving Exkivity, it is important to recognize, evaluate, and appropriately manage this adverse effect in a timely manner.
During treatment with Exkivity, patients should pay close attention to changes in their pulmonary symptoms. New or progressive pulmonary symptoms of unknown origin, such as persistent or worsening dyspnea, frequent cough (especially dry cough), fever, and chest pain, should raise suspicion for possible manifestations of interstitial lung disease/lung inflammation.
To reduce the risk of interstitial lung disease/lung inflammation, patients should undergo a thorough physical examination to assess their lung health status and risk factors prior to treatment with Exkivity. During treatment, patients should strictly follow their doctor's instructions, take their medications on time, and have regular follow-ups. At the same time, patients should also pay attention to maintaining good lifestyle habits and mentality, and avoid adverse effects on the lungs caused by factors such as overwork and mood swings.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:2622025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:4832024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:2672025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:2772025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:2582025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3032025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:2652025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:2442025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: